Last reviewed · How we verify
OK432
At a glance
| Generic name | OK432 |
|---|---|
| Also known as | Picibanil |
| Sponsor | Richard JH Smith |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OK432 (Picibanil) in the Treatment of Lymphatic Malformations (PHASE2)
- The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak (NA)
- Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations (PHASE2, PHASE3)
- Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer (PHASE4)
- Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432 (PHASE4)
- Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer (PHASE1, PHASE2)
- Study of Chemo-Immunotherapy in Head and Neck Cancer Patients (PHASE1)
- Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OK432 CI brief — competitive landscape report
- OK432 updates RSS · CI watch RSS
- Richard JH Smith portfolio CI